1. Are calcineurin inhibitors-free regimens ready for prime time?
Flavio Vincenti 
Kidney International 
Volume 82, Issue 10, Pages (November 2012)
DOI: /ki
Copyright © 2012 International Society of Nephrology Terms and Conditions

2. Figure 1
T-cell activation requires two signals. APC, antigen-presenting cell; MHC, major histocompatibility complex; TCR, T-cell receptor.
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions

3. Figure 2
Belatacept binds with high affinity to CD86 and Cd80 and prevents T-cell activation. APC, antigen-presenting cell; MHC, major histocompatibility complex; TCR, T-cell receptor.
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions

4. Figure 3
The low intensity belatacept treatment regimen in the phase III studies (BENEFIT and BENEFIT-EXT). i.v., intravenous.
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions

5. Figure 4
The projected mean graft half-life based on the clinical profile at 3 years for the BENEFIT and BENEFIT-EXT trials (for the approved low intensity regimen). CsA, cyclosporine; LI, less intensive regimens.
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions

6. Figure 5
The mechanism of action of tofacitinib. JAK, Janus kinase; STAT, signal transducer and activator of transcription.
Kidney International  , DOI: ( /ki )
Copyright © 2012 International Society of Nephrology Terms and Conditions